Navigation Links
MDA Awards Valerion Therapeutics $1.2 Million to Continue Myotubular Myopathy Research
Date:5/30/2013

Tucson, Ariz. (PRWEB) May 30, 2013

The Muscular Dystrophy Association has awarded Valerion Therapeutics $1,195,762 to continue development of an experimental cell-penetrating treatment that may represent a unique approach to treating myotubular myopathy (MTM).

The experimental treatment, 3E10Fv-MTM1, uses a cell-penetrating antibody to deliver myotubularin to muscle fibers. Myotubularin is the protein that is deficient in MTM1.

Researchers at the Concord, Mass., biotech have taken a different approach to creating an effective enzyme-replacement therapy by utilizing an antibody-protein fusion that can penetrate the muscle cell. After receiving injections of 3E10Fv-MTM1 for only two weeks, mice showed improved muscle strength, function and structure.

“We are interested in this technology because it may provide a novel method of delivering proteins to muscle,” said MDA Vice President of Research Jane Larkindale. “In January, the company published data that showed that the technology allowed the protein to get into the muscles of a mouse model of the disease, where it had a positive effect on the disease course. It also may be able to be applied to other proteins for other diseases in MDA's program."

MTM is an inherited muscle disease that can cause severe, general muscle weakness complicating basic activities such as breathing and swallowing.

The award was made through MDA Venture Philanthropy (MVP), the drug development arm of MDA. It will allow the company to continue testing 3E10Fv-MTM1 in mice and develop a pharmaceutical grade treatment that eventually may be tested in individuals with MTM.

"We are extremely grateful for the continued support of MDA,” said Dustin Armstrong, Ph.D., vice president, research at Valerion Therapeutics. “This preclinical funding will advance testing of our myotubular myopathy product candidate and further validate the potential of our therapeutic platform. Valerion is committed to utilizing our antibody-based delivery system to target genetic diseases, and our partnership with MDA provides additional encouragement for addressing these neuromuscular disorders with high unmet need."

MDA began supporting development of this therapy in 2010 through a grant to Armstrong, who was chief scientific officer at 4s3 Bioscience at the time. 4s3 is now Valerion Therapeutics, taking its name from the Latin term valere meaning “to flourish, be strong and healthy.”

To learn more, read "MTM: MDA Funds Development of Myotubularin-Based Treatment."

About Valerion
Valerion Therapeutics (formerly 4s3 Bioscience) is a biotechnology company focused on developing therapies for orphan genetic diseases using a novel antibody-based targeting system.

Valerion takes its name from the Latin word valere meaning “to flourish, to be strong and healthy.”
Valerion’s platform technology allows for enhanced intracellular delivery of active biological therapeutics for neuromuscular diseases, including enzyme-deficiency disorders and muscular dystrophies. Currently, the company’s lead preclinical programs focus on the unmet medical needs of myoytubular myopathy and myotonic dystrophy. Valerion completed a $20 Million Series A investment with Alopexx Enterprises and Genzyme Ventures in 2012. In addition to this venture funding, the company has obtained competitive grant support from the Massachusetts Life Sciences Center (MLSC), the NIH and the Muscular Dystrophy Association.
For more information please go to 4s3bioscience.com.

About MDA

MDA is the nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, ALS and related diseases today affecting more than 1 million Americans. It does so by funding research, providing comprehensive health care and support services, and through advocacy and education.

In addition to funding more than 250 research projects worldwide, MDA maintains a national network of 200 medical clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides local summer camp opportunities for thousands of youngsters living with progressive muscle diseases.

For more information, visit mda.org and follow us on Facebook (facebook.com/MDAnational) and Twitter @MDAnews.

  • MDA-

Read the full story at http://www.prweb.com/releases/2013/5/prweb10782871.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. CSL® (Creative Systems Lighting) Wins Two 2013 Green GOOD DESIGN™ Awards
2. T.E.N. Announces Nominees for The 2013 ISE® West Awards
3. HMHP Wound Care Earns ‘Center of Distinction’ Awards
4. Connecticut Community Foundation Awards More Than $373,000 in Grants & Sponsorships to Area Nonprofits
5. USA Book News Announces Simon Says, By William Poe; Award-Winner In 2013 International Book Awards
6. New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury
7. Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards
8. ISM Announces Winners of 2013 Top 15 CRM Software Awards for both ‘Enterprise’ and ‘Small & Medium Business’ Solutions
9. Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards
10. Dorland Health Announces the 2013 Case In Point Platinum Awards Winners
11. Wolters Kluwer Health receives 13 awards from the ASHPE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: